E
TSVT

Ergoteles’s 2seventy bio TSVT Stock Holding History

Ergoteles’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,100
Closed -$428K – 2011
2022
Q1 		$428K Buy
+25,100
New +$426K 0.02% 717

Other funds holding TSVT

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Ergoteles's TSVT Position: Q2 2022 in Review

Ergoteles sold out of 2seventy bio (TSVT) in Q2 2022, closing a stake of 25,100 shares — an estimated $428K sold.

Ergoteles first reported a position in TSVT in Q1 2022 and held it in 1 quarter. The position peaked at $428K in Q1 2022. 132 funds tracked by Wall St. Rank hold TSVT as of Q2 2022.

  • Ergoteles reported no remaining 2seventy bio position as of Q2 2022 after selling out during the quarter.
  • Ergoteles sold 25,100 2seventy bio shares in Q2 2022, an estimated $428K.
  • Ergoteles first reported a position in 2seventy bio in Q1 2022 and held it in 1 quarter.
  • Ergoteles's 2seventy bio position peaked at $428K in Q1 2022.
  • 132 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.